+A -A

Comparative View:

2Q19 Create chart
Net sales revenues 1,144,658
Change in Fair Value of Biological Assets 77,464
Cost of Goods Sold -733,884
Depreciation / Amortization / exhaustion -110,510
Exhaustion of biological assets -30,064
Gross Profit 347,664
Selling Expenses -169,214
General and Administrative Expenses -46,499
Management Compensation -4,080
Other Operating Compensation 5,931
Equity income from subsidiaries null
Operating Profit before Financial Income and Equity 133,802
Financial Income 19,389
Financial Expenses -56,453
Income Before Income Tax and Social Contribution 96,738
Income and social contribution taxes - current -16,116
Income Tax and Social Contribution - Deferred -11,244
Effect profit from discontinued operation 0
Net Income 69,378
Recurring Net Income 69,480
Recurring EBITDA 213,303
EBITDA Margin 18.6 %

* Because of the date of the merger between Duratex and Satipel, 31.08.09, include data only from the "old" Duratex

**from 1Q 12 the data does not include discontinued operation, Deca Piazza